

Excess mortality in HCV-treated PLWH with

direct-acting antivirals compared to HIV

monoinfection despite controlled HIV:

Results from the ANRS-CO4 FHDH cohort

María Bernarda REQUENA

Inserm UMR-S 1136 – Sidaction grant

maria.requena@iplesp.upmc.fr





Background

- Liver disease: one of the main causes of death in PLWH¹
 - Partly attributable to HIV/HCV coinfection.
- Since 2014, DAAs for HCV: 95 % cure and \downarrow hepatic complications^{2,3}.

Cure \rightarrow *sustained virologic response (SVR12)*

= negative PCR 12 weeks after treatment completion.

Despite cure in HCV monoinfection:

• Morbid events


alcohol and diabetes


- Excess mortality⁴
- Small number of studies on HIV/HCV coinfection⁵

Higher risk of death in DAA cured and HIV controlled patients ?

¹ Croxford S et al. 2017; ² Carrat et al. 2019; ³ Janjua et al. 2021; ⁴ Butt et al. 2020; ⁵ Chalouni M et al. 2021


Objectives





П


- To all-cause mortality in HIV mono-infected individuals under virological control
- Adjusting for risk factors identified in (I)



Objective I

Identification of risk factors associated with all-cause mortality in DAA cured PLWH


I. Methodology




	DAA cured, HIV VL < 200 copies/mL for 6 months before SVR12 (n =3 599)						
	Characteristics at SVR12	N	Median [IQR] or n (%)				
	Age (years)	3,599	52.7 [48.4 ; 56.3]				
Î	Men	3,599	2 642 (73.4%)				
	Origin	3,599					
	Metropolitan France		2 729 (75.8%)				
	Subsaharan Africa		252 (7.0%)				
	Other		618 (17.2%)				
Î Î	BMI (kg/m²)	3,487	22.8 (20.4-25.3)				
H	Time since first + HCV PCR (years)	3,564	7.4 [3.0 ; 11.2]				
0	Transmission route HCV	3,599					
	Intravenous drug user (IDU)		2 064 (57.3%)				
®.́ [℃]	Sexual		763 (21.2%)				
0``0	Transfusion		117 (3.3%)				
	Unknown		485 (13.5%)				
	Other		170 (4.7%)				
	Cirrhosis before HCV treatment	3,599	316 (8.8 %)				

6

DAA cured, HIV VL <200 copies/mL (n =3 599)					
Characteristics at SVR12	Ν	Median [IQR] or n (%)			
Smoking (first visit)	2,211	1078 (48.8%)			
Alcohol (daily)	1,740	728 (22.0%)			
None		1,040 (59.8%)			
<40 g		577 (33.2%)			
>40 g		123 (7.1%)			
Treatment duration (weeks)	3,537	12.4 [12.0 ; 13.3]			
Year of HCV treatment initiation	3,599	2015 [2015 ; 2016]			
Year of first + HIV diagnosis	3,592	1992 [1987 ; 2002]			
CD4 ± 6 months (c/mm ³)	3,599	658 [464 ; 886]			
Nadir CD4 \pm 6 months (c/mm ³)	3,599	169 [75 ; 285]			
AIDS	3,599	925 (25.7%)			



HCV treatment



9

Risk factors associated with mortality in DAA cured HIV/HCV coinfected participants

Multivariable analysis (Cox)		Ν	deaths	HR	p
Transmission route HIV					0.05
N	1SM	873	11	1.00	
ID	טט	1 605	73	1.89 [0.97-3.69]	
0	Other	1 121	27	1.22 [0.58-2.57]	
Men		2 649	80	1.06 [0.68-1.66]	0.79
Age at SVR12 (years)					0.02
<	50	1 185	17	1.00	
50	0-60	2 022	77	1.79 [1.04-3.06]	
≥	60	392	17	2.54 [1.29-5.01]	
AIDS be	efore SVR12	925	39	1.18 [0.78-1.79]	0.43
CD4 Na	adir (log2 c/mL)	3 599	111	0.98 [0.89-1.09]	0.70
Cirrhosis before SVR12		316	35	3.56 [2.36-5.37]	<0.001
Alcohol		702	30	1.82 [1.10-2.99]	0.02
BMI (kg/m ²)					0.01
<	18.5	446	21	2.14 [1.30-3.55]	
18	8.5-24.99	2 223	65	1.00	
≥	25	930	25	0.92 [0.58-1.47]	


10

HIV + DAA cured HIV

Objective II

Mortality comparison between DAA cured HIV/HCV coinfected and HIV monoinfected


II. Methodology



		HIV VL < 200 copies/mL for 6 months before exposed SVR12 date				
			E-: HIV monoinfected. (n = 28,846)		E+: HIV/HCV coinfected cured by DAA (n =3,574)	
Cł	naracteristics at SVR12 +/- 6 mo	Ν	Median [IQR] or n (%)	Ν	Median [IQR] or n (%)	
	ge (years)	28 846	52.0 [47.2 ; 55.9]	3 574	52.6 [48.4 ; 56.3]	
ÌI₽́ M	en	28 846	22 085 (76.6%)	3 574	2 649 (74.1%)	
Or	rigin	28 846		3 574		
<u>∧.@</u> .	Metropolitan France		19 459 (67.5%)		2 706 (75.7%)	
	Sub-Saharan Africa		4 751 (16.5%)		252 (7.1%)	
	Other		4 636 (16.1%)		616 (17.2%)	
HIV transmission route		28 846		3 574		
®< ⁰ ₀	IDU		9 135 (31.6%)		1 580 (44.2%)	
	MSM		8 686 (30.1%)		873 (24.4%)	
	Other		11 025 (38.2%)		1121 (31.4%)	

HIV VL < 20	0 copies/mL for (6 months before exposed SVR12 date
-------------	-------------------	------------------------------------

	E-: HIV monoinfected. (n = 28,846)		E+: HIV/HCV coinfected cured by DAA. (n =3,574)	
Characteristics at SVR12 +/- 6 months	Ν	Median [IQR] or n (%)	Ν	Median [IQR] or n (%)
Year of first HIV+ diagnosis	28,789	1999 [1992 ; 2008]	3,567	1992 [1987 ; 2002]
Time having VL <200 copies/mL (years)	28,846	7.87 [3.36 ; 12.25]	3,574	9.31 [5.46 ; 13.62]
, AIDS before index date	28,846	5,988 (20.8%)	3,574	900 (25.2%)
BMI (kg/m2)	28,844	23.1 [21.0; 25.4]	3,426	22.8 [20.4 ; 25.3]
CD4 ± 6 months (cells/mm3)	28,846	633 [442 ; 860]	3,574	631 [442 ; 867]
CD4 Nadir ± 6 months (cells/mm3)	28,846	211 [86 ; 340]	3,574	170 [76 ; 286]
Alcohol (daily)	4,165		1,740	
✓ None		2,680 (64.4%)		1,040 (59.8%)
<40 g		1,270 (30.5%)		577 (33.2%)
>40 g		215 (5.2%)		123 (7.1%) 14



II. Conclusion

• **Higher** risk of death in first 36 months of SVR in DAA cured HIV/HCV co-infected patients / HIV monoinfected patients (HR = 1.60)

> despite HCV cure, HIV viral suppression and after controlling for variables associated with mortality.

- Similar absolute risk of death in HIV/HCV coinfected participants cured by DAAs between 0-18 months and 18-36 months
 - > while **lower** risk of death in HIV monoinfected participants in the 18-36 months / 0–17 months period.

Previous findings :

Higher all-cause mortality in coinfected	Mortality drop in HIV patients
Alejos B. <i>et al</i> Medicine 2016 May MT. <i>et al</i> J Acquir Immune Defic Syndr. 2015 Chalouni M. <i>et al</i> J Hepatol 2020	Fontela C <i>et al</i> . Sci Rep 2020 Croxford <i>et al.</i> Lancet Public Health. 2017

ACKNOWLEDGEMENTS

Participants of the ANRS-CO4 FHDH cohort.

TEAM

UMRS-1136 IPLESP

K. Lacombe, F. Carrat.

FHDH - S. Grabar, D. Costagliola, V. Potard, L. Lievre, J.Bellet.

FUNDING

Sidaction.





Institut Pierre Louis d'Épidémiologie et de Santé Publique Pierre Louis Institute of Epidemiology and Public Health